JP2022537964A5 - - Google Patents
Info
- Publication number
- JP2022537964A5 JP2022537964A5 JP2021574283A JP2021574283A JP2022537964A5 JP 2022537964 A5 JP2022537964 A5 JP 2022537964A5 JP 2021574283 A JP2021574283 A JP 2021574283A JP 2021574283 A JP2021574283 A JP 2021574283A JP 2022537964 A5 JP2022537964 A5 JP 2022537964A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- stereoisomer
- acceptable salt
- compound according
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/091712 | 2019-06-18 | ||
| CN2019091712 | 2019-06-18 | ||
| US202063035381P | 2020-06-05 | 2020-06-05 | |
| US63/035,381 | 2020-06-05 | ||
| PCT/US2020/037853 WO2020257145A1 (en) | 2019-06-18 | 2020-06-16 | Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537964A JP2022537964A (ja) | 2022-08-31 |
| JP2022537964A5 true JP2022537964A5 (https=) | 2023-06-22 |
| JP7657740B2 JP7657740B2 (ja) | 2025-04-07 |
Family
ID=71575774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021574283A Active JP7657740B2 (ja) | 2019-06-18 | 2020-06-16 | Ｊａｋキナーゼのピラゾロピリミジンスルホン阻害剤およびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11453671B2 (https=) |
| EP (1) | EP3986901A1 (https=) |
| JP (1) | JP7657740B2 (https=) |
| KR (1) | KR20220024405A (https=) |
| CN (1) | CN114008051B (https=) |
| AU (1) | AU2020297415A1 (https=) |
| BR (1) | BR112021025618A2 (https=) |
| CA (1) | CA3140024A1 (https=) |
| CL (1) | CL2021003341A1 (https=) |
| CO (1) | CO2022000118A2 (https=) |
| CR (1) | CR20210661A (https=) |
| IL (1) | IL288957A (https=) |
| MA (1) | MA56518A (https=) |
| MX (1) | MX2021015319A (https=) |
| PE (1) | PE20220577A1 (https=) |
| PH (1) | PH12021552998A1 (https=) |
| TW (1) | TW202115068A (https=) |
| WO (1) | WO2020257145A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202115069A (zh) | 2019-06-18 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | Ｊａｋ激酶之經四唑取代之吡唑并嘧啶抑制劑及其用途 |
| KR102767443B1 (ko) * | 2022-04-14 | 2025-02-12 | 한국화학연구원 | 퀴녹살린 카르복스아마이드 유도체 및 이를 유효성분으로 포함하는 교모세포종의 예방 또는 치료용 약학적 조성물 |
| KR20250011137A (ko) | 2022-05-11 | 2025-01-21 | 피아이 인더스트리스 엘티디. | 바이사이클릭 화합물 및 해충 방제제로서 이의 용도 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| US6034057A (en) | 1995-07-06 | 2000-03-07 | Zeneca Limited | Peptide inhibitors of fibronectine |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| DE60214428T2 (de) | 2001-12-20 | 2007-09-20 | Bayer Healthcare Ag | 1, 4-dihydro-1, 4-diphenylpyridin-derivate |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| CA2676665A1 (en) * | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | Modulators of mitotic kinases |
| CN101616921A (zh) * | 2007-01-30 | 2009-12-30 | 比奥根艾迪克Ma公司 | 1-H-吡唑并(3,4b)嘧啶衍生物及其作为有丝分裂激酶调节剂的用途 |
| CN102131389A (zh) | 2008-06-20 | 2011-07-20 | 健泰科生物技术公司 | 三唑并吡啶jak抑制剂化合物和方法 |
| EP2348860B1 (en) | 2008-10-31 | 2015-05-27 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| AP2015008433A0 (en) | 2012-11-09 | 2015-05-31 | Jacobus Pahrmaceutical Company Inc | Heteroaryl derivatives and uses thereof |
| JP2017516850A (ja) | 2014-05-23 | 2017-06-22 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｊａｋ阻害剤である５−クロロ−２−ジフルオロメトキシフェニルピラゾロピリミジン化合物 |
| TW201720828A (zh) * | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| JP6936236B2 (ja) * | 2016-02-18 | 2021-09-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 治療化合物、組成物及びその方法の使用 |
| CR20190310A (es) | 2016-12-29 | 2019-08-21 | Hoffmann La Roche | Compuestos de pirazolopirimidina y métodos de uso de los mismos |
| JP2020510061A (ja) | 2017-03-14 | 2020-04-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ピラゾロクロロフェニル化合物、組成物及びその使用方法 |
| CN110678467B (zh) * | 2017-05-22 | 2023-06-13 | 豪夫迈·罗氏有限公司 | 治疗化合物和组合物及其使用方法 |
| MX387969B (es) | 2017-05-22 | 2025-03-19 | Hoffmann La Roche | Composiciones y compuestos terapéuticos, y métodos para su uso. |
| EP3740488A1 (en) * | 2018-01-15 | 2020-11-25 | F. Hoffmann-La Roche AG | Pyrazolopyrimidine compounds as jak inhibitors |
| AU2020210455B2 (en) * | 2019-01-25 | 2023-02-02 | Beijing Scitech-Mq Pharmaceuticals Limited | Acylamino bridged heterocyclic compound, and composition and application thereof |
| TW202115069A (zh) | 2019-06-18 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | Ｊａｋ激酶之經四唑取代之吡唑并嘧啶抑制劑及其用途 |
| EP3986899A1 (en) | 2019-06-18 | 2022-04-27 | F. Hoffmann-La Roche AG | Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof |
-
2020
- 2020-06-16 PH PH1/2021/552998A patent/PH12021552998A1/en unknown
- 2020-06-16 BR BR112021025618A patent/BR112021025618A2/pt not_active Application Discontinuation
- 2020-06-16 WO PCT/US2020/037853 patent/WO2020257145A1/en not_active Ceased
- 2020-06-16 AU AU2020297415A patent/AU2020297415A1/en not_active Abandoned
- 2020-06-16 KR KR1020227000044A patent/KR20220024405A/ko not_active Ceased
- 2020-06-16 JP JP2021574283A patent/JP7657740B2/ja active Active
- 2020-06-16 CN CN202080044750.2A patent/CN114008051B/zh active Active
- 2020-06-16 CR CR20210661A patent/CR20210661A/es unknown
- 2020-06-16 PE PE2021002182A patent/PE20220577A1/es unknown
- 2020-06-16 TW TW109120272A patent/TW202115068A/zh unknown
- 2020-06-16 MX MX2021015319A patent/MX2021015319A/es unknown
- 2020-06-16 CA CA3140024A patent/CA3140024A1/en active Pending
- 2020-06-16 MA MA056518A patent/MA56518A/fr unknown
- 2020-06-16 US US16/902,499 patent/US11453671B2/en active Active
- 2020-06-16 EP EP20739492.5A patent/EP3986901A1/en active Pending
-
2021
- 2021-12-13 IL IL288957A patent/IL288957A/en unknown
- 2021-12-14 CL CL2021003341A patent/CL2021003341A1/es unknown
-
2022
- 2022-01-12 CO CONC2022/0000118A patent/CO2022000118A2/es unknown
- 2022-08-24 US US17/821,851 patent/US20230016791A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022537964A5 (https=) | ||
| Weng et al. | Cocrystal engineering of itraconazole with suberic acid via rotary evaporation and spray drying | |
| CN1360499A (zh) | 含有非诺贝特的药物组合物及其制备方法 | |
| CN1080120C (zh) | 药物组合物 | |
| JP2023549226A5 (https=) | ||
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| JP2014523445A5 (https=) | ||
| JP2018534348A5 (https=) | ||
| JP2022502500A5 (https=) | ||
| JP2019510787A5 (https=) | ||
| JP2022507251A (ja) | Ｐ２ｘ３調節剤としての置換イミダゾピリジン化合物の結晶形態およびそれらの使用 | |
| JP2011500621A5 (https=) | ||
| JP2007522162A5 (https=) | ||
| US7208598B2 (en) | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | |
| CN108358917B (zh) | 含有碱性稠环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法 | |
| JP2018537513A5 (https=) | ||
| JP2019530674A5 (https=) | ||
| Durham et al. | Spray dried aerosol particles of pyrazinoic acid salts for tuberculosis therapy | |
| Hegde et al. | Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS) | |
| WO2021000785A1 (zh) | 作为詹纳斯激酶1选择抑制剂的吡咯并[2,3-b]吡啶衍生物 | |
| Ueda et al. | Improvement in inhalation properties of theophylline and levofloxacin by co-amorphization and enhancement in its stability by addition of amino acid as a third component | |
| CN104546819A (zh) | 二咖啡酰奎宁酸在治疗系统性自身免疫性疾病中的用途 | |
| CN116437929A (zh) | 抗微生物化合物的吸入制剂 | |
| JP2018521001A (ja) | 化合物 （ｓ）−３−｛４−［５−（２−シクロペンチル−６−メトキシ−ピリジン−４−イル）−［１，２，４］オキサジアゾール−３−イル］−２−エチル−６−メチル−フェノキシ｝−プロパン−１，２−ジオールの結晶形 | |
| JP2019516765A5 (https=) |